PRF Technologies Ltd. (PRFX) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 6 wire items for PRFX, including 3 SEC filings, 2 press releases and news items and 1 13D/G filing. The most recent was published Nov 5, 2026.

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

Financial highlights

Full financials
Revenue, FY2025
$17.0K
Net income, FY2025
-$5.02M
Net margin
-29541.2%
Free cash flow, FY2025
-$3.96M
Cash
$3.13M

For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.

News · 26 weeks38+100%
2026-05-10: 22026-05-17: 22026-05-24: 42026-05-31: 02026-06-07: 02026-06-14: 12026-06-21: 42026-06-28: 22026-07-05: 22026-07-12: 22026-07-19: 22026-07-26: 22026-08-02: 02026-08-09: 02026-08-16: 02026-08-23: 02026-08-30: 42026-09-06: 22026-09-13: 22026-09-20: 02026-09-27: 12026-10-04: 02026-10-11: 02026-10-18: 22026-10-25: 02026-11-01: 4
2026-05-102026-11-01
Mix1590d
  • SEC Filings8(53%)
  • Other6(40%)
  • 13D/G1(7%)
Activity · 52 weeks7844 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Latest news

25 items

PRFX FAQ

10 questions
  • What does PRF Technologies Ltd. do?
    PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.
  • What is the latest news on PRFX?
    In the last 30 days Quantisnow tracked 6 wire items for PRFX: 3 SEC filings, 2 press releases and news items and 1 13D/G filing. The most recent was published on November 5, 2026.
  • What is PRFX revenue?
    PRF Technologies Ltd. (PRFX) reported $17.0K of revenue for fiscal 2025 (ended Dec 31, 2025).
  • Is PRFX profitable?
    No. PRF Technologies Ltd. reported a net loss of $5.02M for fiscal 2025 (ended Dec 31, 2025).
  • How much cash and debt does PRFX have?
    PRF Technologies Ltd. reported $3.13M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • Where does PRFX stock trade?
    PRF Technologies Ltd. (PRFX) is listed on NASDAQ.
  • What sector and industry is PRFX in?
    PRF Technologies Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • When did PRF Technologies Ltd. go public?
    PRF Technologies Ltd. (PRFX) completed its IPO in 2020.
  • What companies are similar to PRFX?
    Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare PRFX side-by-side with any of them on Quantisnow.
  • How can I track PRFX on Quantisnow?
    Quantisnow aggregates PRF Technologies Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PRFX to receive live email and push alerts on every new disclosure.